US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Tradr 2X Long SRPT Daily ETF

6.89

-0.2000-2.82%

Post-market: 7.070.1800+2.61%18:01 EDT

Volume:43.65K

Turnover:308.90K

Market Cap:3.62M

PE:- -

High:7.16

Open:6.93

Low:6.89

Close:7.09

52wk High:29.40

52wk Low:6.74

Shares:525.00K

Float Shares:525.00K

Volume Ratio:0.95

T/O Rate:8.31%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)

Sarepta's Elevidys Faces 'Little' Pressure After Regenxbio Data, Wedbush Says

MT Newswires Live

Sarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush Says

MT Newswires Live

Sarepta Therapeutics Shares Down 3.3% After Lower Q1 Sales for Gene Therapy

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SRPU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SRPU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SRPU\",,,,,undefined,":{"symbol":"SRPU","market":"US","secType":"STK","nameCN":"Tradr 2X Long SRPT Daily ETF","latestPrice":6.89,"timestamp":1779480000000,"preClose":7.09,"halted":0,"volume":43647,"hourTrading":{"tag":"盘后","latestPrice":7.07,"preClose":6.89,"latestTime":"18:01 EDT","volume":3006,"amount":21151.33,"timestamp":1779487311494,"change":0.18,"changeRate":0.026125,"amplitude":0.026125},"delay":0,"changeRate":-0.028208744710860392,"floatShares":525000,"shares":525000,"eps":0,"marketStatus":"Closed Memorial Day","change":-0.2,"latestTime":"05-22 16:00:00 EDT","open":6.93,"high":7.1585,"low":6.89,"amount":308904,"amplitude":0.03787,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"exchange":"CBOE","adjPreClose":7.09,"sharesOutstanding":310000,"nav":6.8774,"aum":3610630.4,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":7.07,"preClose":6.89,"latestTime":"18:01 EDT","volume":3006,"amount":21151.33,"timestamp":1779487311494,"change":0.18,"changeRate":0.026125,"amplitude":0.026125},"volumeRatio":0.9536941286749842,"impliedVol":7.8754,"impliedVolPercentile":0.993},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SRPU\",,,,,undefined,":{"symbol":"SRPU","floatShares":525000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.9536941286749842,"shares":525000,"dividePrice":0,"high":7.1585,"amplitude":0.03787,"preClose":7.09,"low":6.89,"week52Low":6.74,"pbRate":"--","week52High":29.4,"institutionHeld":0,"latestPrice":6.89,"eps":0,"divideRate":0,"volume":43647,"delay":0,"ttmEps":0,"open":6.93,"prevYearClose":15.25,"prevWeekClose":6.89,"prevMonthClose":11.016,"prevQuarterClose":12.22,"fiveDayClose":7.52,"twentyDayClose":10.4054,"sixtyDayClose":8.91},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SRPU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SRPU\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SRPU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SRPU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2636641856","title":"J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636641856","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636641856?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:16","pubTimestamp":1779192981,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Hold rating on Sarepta Therapeutics, with a price target of $19.00. The c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-hold-on-sarepta-therapeutics-srpt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-hold-on-sarepta-therapeutics-srpt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0106261372.USD","LU0210528500.USD","LU0267386448.USD","IE00BJT1NW94.SGD","IE0009355771.USD","LU2264538146.SGD","LU2271345857.HKD","SRPU","LU1989772923.USD","BK4139","BK4127","IE00B2B36J28.USD","LU0320765646.SGD","LU1720051108.HKD","LU0158827781.USD","BK4585","LU2089284900.SGD","LU2023251221.USD","LU2357305700.SGD","LU0795875086.SGD","LU0234570918.USD","LU1363072403.SGD","LU1989772840.SGD","SRPT","IE0002141913.USD","LU0053666078.USD","LU1720051017.SGD","BK4588","LU1732799900.SGD","IE00BFTCPJ56.SGD","LU0528227936.USD","BK4516","IE00BJJMRZ35.SGD","LU0314104364.USD","LU1244550494.USD","LU0882574139.USD","LU2111349929.HKD","LU0912757837.SGD","LU2089283258.USD","LU1732800096.USD","BK4581","BK4504","LU1064131342.USD","LU2133065610.SGD","LU1244550221.USD","LU1548497426.USD","LU0225283273.USD","LU1244550577.SGD","LU0795875169.SGD","LU0390134368.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635103519","title":"Sarepta's Elevidys Faces 'Little' Pressure After Regenxbio Data, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2635103519","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635103519?lang=en_us&edition=fundamental","pubTime":"2026-05-15 23:29","pubTimestamp":1778858950,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics'  Elevidys is put under a \"little\" pressure on Regenxbio's  positive trial data in Duchenne muscular dystrophy, Wedbush Securities said in a note Friday.The note pointed to statistically significant correlation between microdystrophin expression and functional improvement in the trial of RGX-202, and should benefit all microdystrophin gene therapy programs/products.\"We see no other big impact on Elevidys,\" it said. \"We do not believe that the relatively small patient number in RGNX's study allows for a fair comparison of microdystrophin expression.\"The report also said the regulatory pathway for RGX-202 remains to be defined.Wedbush kept its outperform rating and a $35 price target.Price: 18.12, Change: -0.56, Percent Change: -3.00","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","BK4139","IE00BJJMRZ35.SGD","BK4563","SRPT","IE00B2B36J28.USD","RGNX","IE00BJT1NW94.SGD","IE0009355771.USD","SRPU","BK4585","IE00BFTCPJ56.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634346352","title":"Sarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2634346352","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634346352?lang=en_us&edition=fundamental","pubTime":"2026-05-09 00:09","pubTimestamp":1778256542,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics' (SRPT) commercial portfolio alone should support a higher valuation, while the company's clinical development programs should add further upside, Wedbush said in a Friday note.We","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SRPT","IE00B2B36J28.USD","SRPU","IE0009355771.USD","IE00BFTCPJ56.SGD","BK4585","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633128182","title":"Sarepta Therapeutics Shares Down 3.3% After Lower Q1 Sales for Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2633128182","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633128182?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:32","pubTimestamp":1778160766,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nFWN41K0YU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","SRPU","IE00BJJMRZ35.SGD","IE0009355771.USD","BK4585","BK4139","IE00B2B36J28.USD","IE0002141913.USD","SRPT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":19,"pageCount":1,"totalSize":74,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/SRPU\",params:#limit:6,delay:false,,,undefined,":[]}}